DBV Technologies S.A. - 20-F Filing Summary (Year Ended Dec 31, 2016)
Business Context and Reporting Period
This Annual Report on Form 20-F covers the fiscal year ended December 31, 2016, for DBV Technologies S.A., a French clinical-stage biopharmaceutical company. The company focuses on developing epicutaneous immunotherapy (EPIT) via its proprietary Viaskin patch technology to treat food allergies. As of the reporting date, the company had no approved products for commercial sale and had discontinued its legacy diagnostic product, Diallertest Milk, in late 2015.
Key Financial Metrics
| Metric (in thousands, except per share) | 2016 (€) | 2015 (€) |
|---|---|---|
| Operating Income | 9,084 | 6,166 |
| Total Expenses | (125,115) | (51,712) |
| Operating Loss | (116,031) | (45,546) |
| Net Loss | (114,531) | (44,674) |
| Loss Per Share (Basic & Diluted) | (4.68) | (2.08) |
| Cash and Cash Equivalents | 256,473 | 323,381 |
| Total Assets | 287,500 | 343,280 |
| Total Liabilities | 44,651 | 21,204 |
| Shareholders' Equity | 242,849 | 322,076 |
Note: The company reported no product revenue in 2016. Operating income was derived primarily from the French Research Tax Credit (CIR) and a collaboration agreement with Nestlé Health Science.
Material Changes vs. Prior Period
- Revenue: Product revenue dropped to zero in 2016 following the discontinuation of Diallertest Milk sales in late 2015. However, total operating income increased 47.3% to €9.1 million, driven by a €7.2 million CIR and €1.6 million in other operating income from the Nestlé collaboration.
- Expenses: Total expenses surged 141.8% to €125.1 million. Research and Development (R&D) expenses more than doubled to €78.8 million (up 130.3%) due to the initiation of pivotal Phase III trials for Viaskin Peanut (PEPITES and REALISE) and the Phase II trial for Viaskin Milk (MILES). General and Administrative expenses increased 107.6% to €35.0 million, and Sales & Marketing expenses jumped to €11.3 million as the company built infrastructure for potential North American commercialization.
- Liquidity: Cash and cash equivalents decreased by €66.9 million to €256.5 million, reflecting a net cash outflow from operating activities of €59.5 million and investment activities of €8.3 million. No significant equity financing occurred in 2016.
Guidance, Outlook, and Risks
- Clinical Outlook: The company expects topline results from the pivotal PEPITES and REALISE Phase III trials for Viaskin Peanut in the second half of 2017. Results for the MILES Phase II trial for Viaskin Milk are expected in the first half of 2018.
- Liquidity Runway: Management estimates that existing cash resources are sufficient to fund operations for at least the next 18 months from the filing date. The company anticipates needing additional capital to complete clinical development and commercialization.
- Key Risks:
- Development Risk: Failure of ongoing clinical trials to demonstrate safety and efficacy could halt the company's primary business model.
- Capital Requirements: The company has incurred significant losses since inception and expects to continue doing so. Failure to raise additional capital could force delays or termination of programs.
- Regulatory Risk: Dependence on FDA and EMA approvals, which are uncertain and time-consuming.
- Internal Controls: A material weakness in internal controls identified in 2015 was remediated as of December 31, 2016.
Investor Verification Checklist
- Verify the enrollment completion and timeline for the PEPITES and REALISE Phase III trials for Viaskin Peanut.
- Confirm the status of the €10 million upfront payment and deferred revenue recognition from the Nestlé Health Science collaboration.
- Monitor the company's cash burn rate against the stated 18-month liquidity runway.
- Review the specific terms of the conditional advances from OSEO and Bpifrance regarding repayment obligations upon commercial success.
- Assess the progress of the commercial-scale manufacturing tool (ES GEN4.0) development.